| Patent application number | Description | Published |
|---|
| 20100240034 | Gene defects and mutant ALK kinase in human solid tumors - In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables new methods for determining the presence of these mutant ALK kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention. | 09-23-2010 |
| 20110021546 | Gene Defects And Mutant ALK Kinase In Human Solid Tumors - In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables new methods for determining the presence of these mutant ALK kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention. | 01-27-2011 |
| Patent application number | Description | Published |
|---|
| 20090081709 | Protein markers of responsiveness to type III receptor tyrosine kinase inhibitors - The invention discloses ten (10) protein markers predictive of cancer resistance or responsiveness to Type III Receptor Tyrosine Kinase (RTK) inhibitors, and provides methods for identifying a cancer that is likely to be resistant to a Type III RTK-inhibiting therapeutic by examining expression and/or activity of one or more of the disclosed biomarkers in a biological sample from the cancer. Methods for identifying a compound that inhibits a cancer resistant to a Type III RTK-inhibiting therapeutic by determining the effect of the compound on one or more of the disclosed marker proteins are also provided. | 03-26-2009 |
| 20090156475 | Gene defects and mutant ALK kinase in human solid tumors - In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables new methods for determining the presence of these mutant ALK kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention. | 06-18-2009 |
| 20100304382 | Gene Defects and Mutant ALK Kinase in Human Solid Tumors - In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables new methods for determining the presence of these mutant ALK kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention. | 12-02-2010 |
| Patent application number | Description | Published |
|---|
| 20090246506 | STRUCTURAL POLYMER INSERT AND METHOD OF MAKING THE SAME - A structural polymer insert. The insert includes a substrate having a surface and an adhesive with the substrate being an admixture of a polypropylene component and a glass fiber component. The surface has a plurality of oxygen atoms, optionally introduced by air plasma, in an amount of 1 to 60 atomic percent of all the atoms present on the surface. The foam adhesive is attached to the surface through one or more reactive moieties resulted from oxidative action of the oxygen atoms. | 10-01-2009 |
| 20100055476 | PLASMA COATINGS AND METHOD OF MAKING THE SAME - According to at least one aspect of the present invention, a method is provided for forming a polymerized coating on a surface of a substrate. In at least one embodiment, the method comprises providing a plasma gun having an outlet; introducing a pre-polymer molecule into the outlet of the plasma gun to form a number of fragments of the pre-polymer molecule as a plasma output including a direct-spray component and an over-spray component; at least partially isolating the direct-spray component and the over-spray component from each other to respectively obtain an isolated directed-spray component and an isolated over-spray component; and depositing at least a portion of the isolated direct-spray component and the isolated over-spray component onto the surface of the substrate through the outlet to form a base polymerized coating. The plasma gun is optionally operated at atmospheric pressure. | 03-04-2010 |
| 20100151236 | SURFACE TREATMENT FOR POLYMERIC PART ADHESION - A surface treatment for polymeric part adhesion and a treated part is provided. In one aspect, a method for adhesively securing a part to a polymeric substrate is provided comprising providing an adhesive layer having a bonding surface having a first oxygen composition, a part having a bondable surface, and a polymeric substrate having a mating surface. Spray from an air plasma device is directed onto at least a portion of the bonding surface of the adhesive to provide a second oxygen composition on the bonding surface of the adhesive layer, with the second oxygen composition being greater than the first oxygen composition. The adhesive layer is secured between the bondable surface of the part and the mating surface of the polymeric substrate. | 06-17-2010 |
| Patent application number | Description | Published |
|---|
| 20090214332 | MULTISTAGE PUMP ASSEMBLY HAVING REMOVABLE CARTRIDGE - A multistage pump assembly includes a manifold having an inlet port configured to be coupled to a supply pipe and an outlet port configured to be coupled to a discharge pipe. The inlet and outlet ports define an end suction, radial outlet port configuration. The pump assembly also includes a cartridge having a sleeve and plurality of pumping stages that define a pump stack received within the sleeve. An outer chamber is defined between the pump stack and the sleeve. Each of the pumping stages includes an impeller mounted along a pump shaft that rotates about a rotation axis. The cartridge is aligned horizontally such that the rotation axis is substantially horizontal. An end plate is positioned between the manifold and the cartridge and includes at least one cartridge engagement surface supporting the cartridge. The end plate is removably coupled to the manifold. | 08-27-2009 |
| 20090246039 | CARRIER ASSEMBLY FOR A PUMP - A pump assembly includes a manifold having an inlet port configured to be coupled to a supply pipe and an outlet port configured to be coupled to a discharge pipe. The pump assembly also includes a cartridge having a pump stack including a plurality of pumping stages. Each pumping stage includes an impeller. The cartridge extends between a first end and a second end. The first end is removably coupled to the manifold. A carrier assembly supports the cartridge. The carrier assembly moves the cartridge between an advanced position and a retracted position. The cartridge engages the manifold in the advanced position and the cartridge is disengaged from the manifold in the retracted position. Optionally, the carrier assembly may include a support frame and at least one rail. The support frame is slidable along the rail and the cartridge is supported by the support frame. | 10-01-2009 |
| 20100098531 | MULTISTAGE PUMP ASSEMBLY - A modular pump assembly has a volute ( | 04-22-2010 |
| 20100247352 | POWER CONNECTORS FOR PUMP ASSEMBLIES - A pump assembly includes a pump housing, a motor coupled to the pump housing being operated to drive fluid through the pump housing, and a control module operatively coupled to the motor. The control module has a power connector with power contacts, where the power connector has a plug interface. The pump assembly also includes first and second plug assemblies configured to be selectively coupled to the power connector. The first and second plug assemblies have first and second mating interfaces both configured to mate with the plug interface of the power connector. The first plug assembly includes a line cord having a pump plug at one end of the line cord and an outlet plug at an opposite end of the line cord. The second plug assembly includes a conduit box having plug contacts configured to be field wired to a power cable within the conduit box. | 09-30-2010 |
| 20100284831 | ADAPTORS FOR MULTISTAGE PUMP ASSEMBLIES - A pump assembly is configured to fit to a predefined pipe layout defined by supply and discharge interfaces that are positioned in a predefined relation to supply and discharged centerlines, respectively. The pump assembly includes a multistage pump having a plurality of pumping stages mounted along a pump shaft rotating along a rotation axis. The multistage pump has an inlet port and a discharge port, and the multistage pump is aligned horizontally such that the rotation axis is oriented parallel to the supply centerline. The pump assembly also includes an adaptor having a pump interface and a pipe interface, wherein the adaptor has an internal fluid channel extending along a non-linear passageway between the pump and pipe interfaces. The pump interface is coupled to one of the inlet and discharge ports of the multistage pump, and the pipe interface is located proximate one of the supply and discharge interfaces. | 11-11-2010 |
